| Year |
Citation |
Score |
| 2023 |
Ahmed S, Wedekind MF, Del Rivero J, Raygada M, Lockridge R, Glod JW, Flowers C, Thomas BJ, Bernstein DB, Kapustina OB, Jain A, Miettinen M, Raffeld M, Xi L, Tyagi M, ... ... Reilly KM, et al. Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants. Cancer Research Communications. PMID 37966258 DOI: 10.1158/2767-9764.CRC-23-0247 |
0.315 |
|
| 2022 |
Yuan M, Eberhart CG, Pratilas CA, Blakeley JO, Davis C, Stojanova M, Reilly K, Meeker AK, Heaphy CM, Rodriguez FJ. Therapeutic Vulnerability to ATR Inhibition in Concurrent and -Deficient/ALT-Positive High-Grade Solid Tumors. Cancers. 14. PMID 35740680 DOI: 10.3390/cancers14123015 |
0.369 |
|
| 2022 |
Fernández-Rodríguez J, Creus-Bachiller E, Zhang X, Martínez-Iniesta M, Ortega-Bertran S, Guha R, Thomas CJ, Wallace MR, Romagosa C, Salazar-Huayna L, Reilly KM, Blakeley JO, Serra-Musach J, Pujana MA, Serra E, et al. A high-throughput screening platform identifies novel combination treatments for Malignant Peripheral Nerve Sheath Tumors. Molecular Cancer Therapeutics. PMID 35511749 DOI: 10.1158/1535-7163.MCT-21-0947 |
0.361 |
|
| 2020 |
Shetty I, Fuller S, Raygada M, Merino MJ, Thomas BJ, Widemann BC, Reilly KM, Pacak K, Del Rivero J. Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma. Endocrinology, Diabetes & Metabolism Case Reports. 2020. PMID 31917677 DOI: 10.1530/Edm-19-0147 |
0.325 |
|
| 2020 |
Yuan M, Reilly K, Pratilas C, Heaphy C, Rodriguez F. NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST Neuro-Oncology. 22: iii417-iii418. DOI: 10.1093/neuonc/noaa222.605 |
0.318 |
|
| 2019 |
Ferner RE, Bakker A, Elgersma Y, Evans DGR, Giovannini M, Legius E, Lloyd A, Messiaen LM, Plotkin S, Reilly KM, Schindeler A, Smith MJ, Ullrich NJ, Widemann B, Sherman LS. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. American Journal of Medical Genetics. Part A. PMID 30908866 DOI: 10.1002/Ajmg.A.61112 |
0.442 |
|
| 2019 |
Thomas B, Fuller S, Ilanchezhian M, Allen D, Allen T, Weiner L, Wisch L, Sherri D, Gillespie A, Raygada M, Arnaldez F, Reilly K, Glod J, Widemann B, Del Rivero J. SUN-341 A Natural History Study for Rare Tumors: An Avenue for Discovering and Understanding Endocrine Cancers Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Sun-341 |
0.407 |
|
| 2017 |
Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. Sarcoma. 2017: 7429697. PMID 28592921 DOI: 10.1155/2017/7429697 |
0.405 |
|
| 2017 |
Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A. Histopathologic Evaluation of Atypical Neurofibromatous Tumors and Their Transformation into Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis 1 Patients - A Consensus Overview. Human Pathology. PMID 28551330 DOI: 10.1016/J.Humpath.2017.05.010 |
0.416 |
|
| 2017 |
Reilly KM, Tuskan RG, Widemann BC. Abstract 5038: Comparison of the dose response of malignant peripheral nerve sheath tumor in vitro growth inhibition of 30 drugs to reported Cmax values Cancer Research. 77: 5038-5038. DOI: 10.1158/1538-7445.Am2017-5038 |
0.354 |
|
| 2016 |
Bradford D, Reilly KM, Widemann BC, Sandler A, Kummar S. Developing therapies for rare tumors: opportunities, challenges and progress. Expert Opinion On Orphan Drugs. 4: 93-103. PMID 32765971 DOI: 10.1517/21678707.2016.1120663 |
0.409 |
|
| 2016 |
Karmakar S, Reilly KM. The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. Cns Oncology. PMID 28001089 DOI: 10.2217/Cns-2016-0024 |
0.409 |
|
| 2016 |
Pisklakova A, McKenzie B, Zemp F, Lun X, Kenchappa RS, Etame AB, Rahman MM, Reilly K, Pilon-Thomas S, McFadden G, Kurz E, Forsyth PA. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Neuro-Oncology. PMID 26962017 DOI: 10.1093/Neuonc/Now006 |
0.383 |
|
| 2015 |
Henrich CJ, Cartner LK, Wilson JA, Fuller RW, Rizzo AE, Reilly KM, McMahon JB, Gustafson KR. Deguelins, Natural Product Modulators of NF1-Defective Astrocytoma Cell Growth Identified by High-Throughput Screening of Partially Purified Natural Product Extracts. Journal of Natural Products. PMID 26467198 DOI: 10.1021/Acs.Jnatprod.5B00753 |
0.303 |
|
| 2015 |
Hirbe AC, Dahiya S, Miller CA, Li T, Fulton RS, Zhang X, McDonald S, DeSchryver K, Duncavage EJ, Walrath J, Reilly KM, Abel HJ, Pekmezci M, Perry A, Ley TJ, et al. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25925892 DOI: 10.1158/1078-0432.Ccr-14-3049 |
0.415 |
|
| 2015 |
Warrington NM, Sun T, Luo J, McKinstry RC, Parkin PC, Ganzhorn S, Spoljaric D, Albers AC, Merkelson A, Stewart DR, Stevenson DA, Viskochil D, Druley TE, Forys JT, Reilly KM, et al. The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. Cancer Research. 75: 16-21. PMID 25381154 DOI: 10.1158/0008-5472.Can-14-1891 |
0.364 |
|
| 2015 |
Reilly KM, Tuskan RG, Widemann BC. Abstract 4199: Developing therapies for rare tumors: Using mouse models of malignant peripheral nerve sheath tumors to complement rare human samples in drug screens Cancer Research. 75: 4199-4199. DOI: 10.1158/1538-7445.Am2015-4199 |
0.426 |
|
| 2014 |
Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. Cancer Research. 74: 7260-73. PMID 25336188 DOI: 10.1158/0008-5472.Can-14-0876 |
0.389 |
|
| 2014 |
Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA. Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells. Phytochemistry Letters. 7: 42-45. PMID 24443661 DOI: 10.1016/J.Phytol.2013.09.007 |
0.325 |
|
| 2014 |
Lee M, Reilly K. Pm-10Cdca7L Functions As A Male-Specific Oncogene In Astrocytoma. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou268.10 |
0.35 |
|
| 2013 |
Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA. Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon. Plos One. 8: e65801. PMID 23762429 DOI: 10.1371/Journal.Pone.0065801 |
0.328 |
|
| 2013 |
Reilly KM. Extending the convergence of canonical WNT signaling and classic cancer pathways for treatment of malignant peripheral nerve sheath tumors. Cancer Discovery. 3: 610-2. PMID 23749527 DOI: 10.1158/2159-8290.CD-13-0192 |
0.356 |
|
| 2013 |
Devkota KP, Wilson J, Henrich CJ, McMahon JB, Reilly KM, Beutler JA. Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth. Journal of Natural Products. 76: 59-63. PMID 23268719 DOI: 10.1021/Np300696G |
0.374 |
|
| 2013 |
Turbyville T, Brafman A, Chen D, Romanchuck K, Beutler J, Reilly K, Lockett S. Abstract 3429: Coordination of cell cycle repression and reduced cytoskeletal tension by the small molecule natural product, Schweinfurthin A. Cancer Research. 73: 3429-3429. DOI: 10.1158/1538-7445.Am2013-3429 |
0.433 |
|
| 2013 |
Reilly KM, Lee M, Schaick JA. Abstract 3005: Cdca7l is a sex-specific modifier of astrocytoma and glioblastoma. Cancer Research. 73: 3005-3005. DOI: 10.1158/1538-7445.Am2013-3005 |
0.407 |
|
| 2013 |
Lee MH, Jones G, Amlin-Van Schaick J, DiFabio C, Whitman M, Shankavarum U, Huynh T, Kim S, Pacak K, Broman KW, Reilly KM. Modifiers of Neurofibromatosis-Associated Tumors and the Potential Role for Catecholamines and Sex Differences Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 73. DOI: 10.1016/B978-0-12-800044-1.00064-7 |
0.301 |
|
| 2012 |
Amlin-Van Schaick JC, Kim S, DiFabio C, Lee MH, Broman KW, Reilly KM. Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. Neuro-Oncology. 14: 160-74. PMID 22234937 DOI: 10.1093/Neuonc/Nor206 |
0.359 |
|
| 2012 |
Amlin-Van Schaick J, Kim S, Broman KW, Reilly KM. Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 23: 277-85. PMID 22160242 DOI: 10.1007/S00335-011-9380-0 |
0.329 |
|
| 2012 |
Brognaro E, Ghods A, Feinstein D, Glick R, Connolly KJ, Meetze K, Boudrow A, Gyuris J, Han M, Hingtgen S, Figueiredo J, Farrar C, Farrar C, Deubgen M, Martinez-Quintanilla J, ... ... Reilly K, et al. LAB-TUMOR MODELS (IN VIVO/IN VITRO) Neuro-Oncology. 14: vi160-vi164. DOI: 10.1093/Neuonc/Nos241 |
0.416 |
|
| 2012 |
Castro Ruiz A, Wilson J, Henrich C, Reilly K, McMahon J, Gustafson K. Antiastrocytoma natural products that target tumor cells with defects in the tumor suppressor neurofibromin Planta Medica. 78. DOI: 10.1055/s-0032-1320719 |
0.316 |
|
| 2012 |
Jones GN, Reilly KM. Dissection of complex genetic and epigenetic interactions underlying nf1 cancer susceptibility using mouse models Neurofibromatosis Type 1: Molecular and Cellular Biology. 2147483647: 287-304. DOI: 10.1007/978-3-642-32864-0_19 |
0.3 |
|
| 2011 |
Gürsel DB, Connell-Albert YS, Tuskan RG, Anastassiadis T, Walrath JC, Hawes JJ, Amlin-Van Schaick JC, Reilly KM. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. Neuro-Oncology. 13: 610-21. PMID 21636709 DOI: 10.1093/Neuonc/Nor035 |
0.388 |
|
| 2011 |
Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, ... ... Reilly KM, et al. Back to the future: proceedings from the 2010 NF Conference. American Journal of Medical Genetics. Part A. 155: 307-21. PMID 21271647 DOI: 10.1002/Ajmg.A.33804 |
0.418 |
|
| 2010 |
Turbyville TJ, Gürsel DB, Tuskan RG, Walrath JC, Lipschultz CA, Lockett SJ, Wiemer DF, Beutler JA, Reilly KM. Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. Molecular Cancer Therapeutics. 9: 1234-43. PMID 20442305 DOI: 10.1158/1535-7163.Mct-09-0834 |
0.523 |
|
| 2010 |
Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. Advances in Cancer Research. 106: 113-64. PMID 20399958 DOI: 10.1016/S0065-230X(10)06004-5 |
0.424 |
|
| 2010 |
Pemov A, Park C, Reilly KM, Stewart DR. Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency. Bmc Genomics. 11: 194. PMID 20307317 DOI: 10.1186/1471-2164-11-194 |
0.445 |
|
| 2010 |
Hawes JJ, Reilly KM. Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis. Toxicologic Pathology. 38: 123-30. PMID 20176786 DOI: 10.1177/0192623309357075 |
0.491 |
|
| 2010 |
Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Research. 70: 1356-66. PMID 20124472 DOI: 10.1158/0008-5472.Can-09-2178 |
0.489 |
|
| 2010 |
Connell-Albert Y, Gursel D, Tuskan R, Anastassiadis T, Hawes J, Schaick JV, Reilly K. Abstract 354: PI-103 and TCN as proliferative inhibitors of the RTK/PI3K/ATK signaling pathways in astrocytomas Cancer Research. 70: 354-354. DOI: 10.1158/1538-7445.Am10-354 |
0.373 |
|
| 2009 |
Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quiñones OA, Reilly KM. Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 20: 214-23. PMID 19347398 DOI: 10.1007/S00335-009-9179-4 |
0.432 |
|
| 2009 |
Reilly KM. Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk. Brain Pathology (Zurich, Switzerland). 19: 121-31. PMID 19076777 DOI: 10.1111/j.1750-3639.2008.00236.x |
0.303 |
|
| 2009 |
Hawes JH, Tuskan RG, Agaki K, Reilly KM. Abstract C12: EGFR signaling controls the chromatin binding status of BMI1 through a CK2/PP1 phosphorylation/dephosphorylation pathway and affects astrocytoma proliferation and neural stem cell differentiation Cancer Research. 69: 4893-4893. DOI: 10.1158/0008-5472.Fbcr09-C12 |
0.396 |
|
| 2008 |
Reilly KM, Van Dyke T. It takes a (dysfunctional) village to raise a tumor. Cell. 135: 408-10. PMID 18984150 DOI: 10.1016/J.Cell.2008.10.009 |
0.466 |
|
| 2008 |
Hawes JJ, Nerva JD, Reilly KM. Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. Journal of Biomolecular Screening. 13: 795-803. PMID 18664715 DOI: 10.1177/1087057108321085 |
0.367 |
|
| 2008 |
Reilly KM, Rubin JB, Gilbertson RJ, Garbow JR, Roussel MF, Gutmann DH. Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. Cancer Research. 68: 5508-11. PMID 18632599 DOI: 10.1158/0008-5472.Can-08-0703 |
0.47 |
|
| 2008 |
Tuskan RG, Tsang S, Sun Z, Baer J, Rozenblum E, Wu X, Munroe DJ, Reilly KM. Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels. Epigenetics : Official Journal of the Dna Methylation Society. 3: 43-50. PMID 18188004 DOI: 10.4161/Epi.3.1.5469 |
0.348 |
|
| 2007 |
Hawes JJ, Tuskan RG, Reilly KM. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Neurogenetics. 8: 121-30. PMID 17216419 DOI: 10.1007/S10048-006-0078-5 |
0.462 |
|
| 2006 |
Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES, Sun Z, Diehl J, Munroe DJ, Tuskan RG. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Research. 66: 62-8. PMID 16397217 DOI: 10.1158/0008-5472.Can-05-1480 |
0.473 |
|
| 2005 |
Gürsel DB, Reilly KM. Models of astrocytoma Drug Discovery Today: Disease Models. 2: 77-83. DOI: 10.1016/J.Ddmod.2005.05.003 |
0.357 |
|
| 2004 |
Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. Journal of Translational Medicine. 2: 40. PMID 15563374 DOI: 10.1186/1479-5876-2-40 |
0.353 |
|
| 2004 |
Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, Smith CD, Tsang S, Munroe DJ, Jacks T. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proceedings of the National Academy of Sciences of the United States of America. 101: 13008-13. PMID 15319471 DOI: 10.1073/Pnas.0401236101 |
0.426 |
|
| 2004 |
Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, ... ... Reilly KM, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Research. 64: 3718-24. PMID 15150133 DOI: 10.1158/0008-5472.Can-03-4079 |
0.442 |
|
| 2002 |
Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, ... ... Reilly K, et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene. 21: 7453-63. PMID 12386807 DOI: 10.1038/Sj.Onc.1205936 |
0.482 |
|
| 2001 |
Reilly KM, Jacks T. Genetically engineered mouse models of astrocytoma: GEMs in the rough? Seminars in Cancer Biology. 11: 177-91. PMID 11407943 DOI: 10.1006/Scbi.2000.0375 |
0.375 |
|
| 2001 |
Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia. 33: 314-23. PMID 11246230 DOI: 10.1002/1098-1136(20010315)33:4<314::Aid-Glia1030>3.0.Co;2-Q |
0.374 |
|
| 2000 |
Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nature Genetics. 26: 109-13. PMID 10973261 DOI: 10.1038/79075 |
0.402 |
|
| 1999 |
Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science (New York, N.Y.). 286: 2172-6. PMID 10591652 DOI: 10.1126/Science.286.5447.2172 |
0.487 |
|
| Show low-probability matches. |